| Medical and Health Sciences | Lifetime | 172 | US 92 | 99.99 |
| Surgery | Lifetime | 45 | US 27 | 99.96 |
| Cardiology and Cardiovascular Medicine | Lifetime | 55 | US 31 | 99.95 |
| Endocrinology, Diabetes and Metabolism | Lifetime | 195 | US 106 | 99.42 |
| Radiology, Nuclear Medicine and Imaging | Lifetime | 667 | US 369 | 98.27 |
| Clinical Pharmacology | Lifetime | 656 | US 269 | 97.12 |
| Internal Medicine | Lifetime | 181 | US 72 | 96.06 |
| Surgery | 2021-2025 | 241 | US 97 | 98.48 |
| Endocrinology, Diabetes and Metabolism | 2021-2025 | 111 | US 56 | 98.42 |
| Cardiology and Cardiovascular Medicine | 2021-2025 | 272 | US 128 | 97.72 |
| Acute Myocardial Infarction Research | Lifetime | 9 | US 8 | 99.96 |
| Lipoproteins and Cardiovascular Health | Lifetime | 10 | US 7 | 99.91 |
| Antiplatelet Therapy and Cardiovascular Diseases | Lifetime | 11 | US 7 | 99.92 |
| Health Systems, Economic Evaluations, Quality of Life | Lifetime | 33 | US 17 | 99.85 |
| Pharmaceutical Economics and Policy | Lifetime | 6 | US 5 | 99.58 |
| Cardiac Imaging and Diagnostics | Lifetime | 62 | US 37 | 99.87 |
| Coronary Interventions and Diagnostics | Lifetime | 31 | US 20 | 99.86 |
| Diabetes Treatment and Management | Lifetime | 53 | US 26 | 99.72 |
| Venous Thromboembolism Diagnosis and Management | Lifetime | 102 | US 40 | 99.64 |
| Atrial Fibrillation Management and Outcomes | Lifetime | 143 | US 69 | 99.55 |
| Diabetes, Cardiovascular Risks, and Lipoproteins | Lifetime | 161 | US 78 | 99.33 |
| Heart Failure Treatment and Management | Lifetime | 181 | US 97 | 99.28 |
| Pharmacology and Obesity Treatment | Lifetime | 71 | US 39 | 98.97 |
| Clinical practice guidelines implementation | Lifetime | 207 | US 63 | 97.45 |
| Cardiovascular Function and Risk Factors | Lifetime | 939 | US 460 | 98.44 |
| Inflammatory mediators and NSAID effects | Lifetime | 383 | US 188 | 97.65 |
| Cardiac Health and Mental Health | Lifetime | 305 | US 167 | 97.83 |
| Blood Pressure and Hypertension Studies | Lifetime | 722 | US 293 | 97.99 |
| Sarcoma Diagnosis and Treatment | Lifetime | 791 | US 383 | 97.37 |
| Cancer, Lipids, and Metabolism | Lifetime | 824 | US 382 | 97.15 |
| Atherosclerosis and Cardiovascular Diseases | Lifetime | 483 | US 194 | 96.86 |
| Management of metastatic bone disease | Lifetime | 286 | US 149 | 96.64 |
| Metabolism, Diabetes, and Cancer | Lifetime | 885 | US 374 | 97.07 |
| Adipokines, Inflammation, and Metabolic Diseases | Lifetime | 956 | US 369 | 96.30 |
| Medication Adherence and Compliance | Lifetime | 658 | US 350 | 92.37 |
| Heparin-Induced Thrombocytopenia and Thrombosis | Lifetime | 420 | US 163 | 92.75 |
| GDF15 and Related Biomarkers | Lifetime | 440 | US 148 | 83.41 |
| Synthesis of β-Lactam Compounds | Lifetime | 623 | US 136 | 85.92 |
| Heart rate and cardiovascular health | Lifetime | 684 | US 203 | 69.10 |
| Lipoproteins and Cardiovascular Health | 2021-2025 | 78 | US 36 | 98.03 |
| Diabetes Treatment and Management | 2021-2025 | 145 | US 63 | 98.39 |
| Antiplatelet Therapy and Cardiovascular Diseases | 2021-2025 | 130 | US 30 | 96.90 |
| Pancreatic function and diabetes | 2021-2025 | 367 | US 139 | 93.73 |
| Metabolism, Diabetes, and Cancer | 2021-2025 | 271 | US 72 | 91.96 |
| Atrial Fibrillation Management and Outcomes | 2021-2025 | 926 | US 227 | 93.92 |
| Diabetes, Cardiovascular Risks, and Lipoproteins | 2021-2025 | 481 | US 117 | 90.47 |
| Pharmacology and Obesity Treatment | 2021-2025 | 997 | US 359 | 57.68 |
| Potassium and Related Disorders | 2021-2025 | 836 | US 273 | 56.80 |
